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Chiral molecules play a vital role in supporting biologically effective drugs. 
Consequently, a majority of pharmaceutical companies seek to isolate the enantiomers 
of molecules in drug design. Enantioselective synthesis can be a valuable tool for 
creating single enantiomers. A particular technique for synthesizing enantiomers is 
desymmetrization, where a prochiral molecule loses its symmetry elements through a 
reaction. In this work, desymmetrization will be done utilizing a diester with a Brønsted 
acid catalyst, to achieve mild reaction conditions for cyclization. Providing these mild 
conditions decreases the chances of side reactions which can happen in harsher 
reaction conditions hindering enantioselectivity. This approach of using organocatalysts 
to perform these cyclizations is novel given cyclizations of this nature typically utilize 
transition metal catalysts. 
This thesis describes the expansion of previous work in the Petersen Group in 
the synthesis of six-membered lactones with multiple stereocenters. Previous work 
utilized prochiral nitrile compounds to synthesize -lactones, and this work provides the 
results of diastereo- and enantioselective desymmetrizations with malonic esters. Once 
cyclization was achieved the reaction was optimized by varying the achiral Brønsted acid 
catalyst used, the temperature, and solvents. After optimization of our first substrate 
containing a bulky phenyl group, a second less bulky alkylating agent was used to 
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The use of small organic molecules in the synthesis of pharmaceuticals and 
natural products has been a long developing field. Almost two centuries ago, the 
phenomenon of chirality was discovered and its function in not only biology, but in  
chemical and pharmaceutical production continues to be studied.1 Derived from the 
Ancient Greek word, cheir, which relates to handedness, chirality of molecules is defined 
by an inability of two mirror image molecules to be superimposable. A pair of non-
superimposable mirror images are called enantiomers. Typically the point of chirality will 
be a carbon atom with four different substituents attached. This center can be referred to 
as a stereocenter and how the substituents are attached will determine the configuration 
of an enantiomer. With the addition of multiple stereocenters, molecules that have 
opposing absolute configurations at each center can still be enantiomers (e.g. A and B 








but will become diastereomers when at least one of those stereocenters retains the 
same absolute configuration (e.g. A and C, A and D, B and C, B and D in Figure 1). 
While enantiomers have indistinguishable physical properties, they can be differentiated 
by how they react with polarized light and other enantioenriched molecules. 
Diastereomers, alternatively, can have varying chemical and even physical properties 
that help distinguish between them. More importantly enantiomers and diastereomers 
can exhibit varying biological effects. In 1933, Easson and Stedman proposed a three-
point interaction of a drug with a receptor site which in many cases will allow for the drug 
to show a specific activity within the body.1 Because of this, the research into chiral 
drugs, specifically the synthesis of enantiomerically pure drugs is a high priority for many 
pharmaceutical companies. Thus, drugs that exhibit bioactivity often have at least one 
chiral center. Seen in a variety of synthetic and naturally occurring compounds, the R or 
S derivatives can have wildly differing biological effects based on chemical site 
receptors. For instance, the drug methadone is “a central-acting analgesic with a high 
affinity for -opioid receptors.”1 This drug typically is used as a racemic (or 1:1 mixture of 
enantiomers) drug, though the R enantiomer has been shown to be almost 25-50 fold 








The prevalence of the racemic drug over the enantiopure drug in the treatment of 
patients is associated with cost as it is cheaper to synthesize the racemate rather than 
isolate the R enantiomer. At the same time, synthesizing enantiopure compounds allows 
pharmaceutical companies the ability to study the bioactivity of one enantiomer over 
another for maximum benefits as well as avoid potential adverse effects.2  A particular 
compound of interest is the lactone motif, which can be found throughout nature and 
serves as a building block to many larger structures. One specific example of a naturally 
occurring substance with a -lactone motif are coumarins (Figure 3), especially those 




Figure 3. Base structure for coumarin and a coumarin derivative 
 
 
Some coumarin derivatives, like (-)-Herbertenolide (Figure 3) have been found to exhibit 
growth suppression of certain pathogenic plant fungi.19 -Lactones, or -valerolactones, 
are not just useful as building blocks for other compounds but also have been deemed 
especially important for the production of biodegradable polymers. Currently 
poly(ethylene glycol), PEG, has been the most widely used polyether in the biomedical 
field.8,12 However, along with its many biomedical and chemical uses, the 
nonbiodegradability of PEG has been seen as an increasing concern. Poly(-
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valerolactones) along with poly(-caprolactones) are aliphatic polyesters that can be 
synthesized from the polymerization of -valerolactones and -caprolactones, 
respectively. These polymers are unique in that they are more biodegradable, have low 
cytotoxicity, and good “permeability to a wide variety of drugs,”8 which makes them more 
viable candidates for PEG analogs. One particular route of polymerization of -
valerolactones has been the controlled ring-opening polymerization (ROP) utilizing 




Figure 4. Ring-opening polymerization (ROP) of -valerolactones 
 
 
It was found that functionalized lactones serve as a valuable portion of this ROP 
methodology though the syntheses to prepare the monomers was “cumbersome” and 
required many steps.13 It was even seen in the work done by Li and associates that the 
thiol-ene adducts of exocyclic unsaturated -valerolactones were more stable than the 
endocyclic unsaturated -valerolactones used in prior work.12 The cyclic lactones 
synthesized by the Petersen group could then serve as facile starting material for ROP 
strategies along with serving as potential building blocks for enantiopure drugs. The 
added value of chirality to polyesters has been shown in the production of poly(hydroxy 
acid)s. Poly(hydroxy acid)s can be synthesized from the ring-opening polymerization of 
-and -lactones as well as lactides and O-carboxyanhydrides, and the backbones of 
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these polymers contain varying side chain groups that depending on their tacticity can 
“modulate the physical, mechanical, and biological properties of the resulting polymer.”7 
 
I.2 Asymmetric Synthesis 
When chiral compounds are synthesized, there is the potential for the products to 
result in either a racemic mixture (an equal production of both the R and S enantiomers) 
or a mixture of enantiomers with enantiomeric excess (ee), where there is a higher 
percentage of either the R or S enantiomer. This selectivity can also be seen for 
diastereomers with varying ratios, or diastereomeric ratios (dr). Enantiomeric or 
diastereomeric ratios can be determined through a variety of chromatographic 
techniques. As diastereomers contain differing chemical properties, they can often be 
separated using standard chemical techniques such as crystallization or 
chromatography. Enantiomers, however, have identical physical properties, and thus 
must be separated utilizing enantioselective methodologies like chiral liquid 
chromatography or kinetic resolution.  
During kinetic resolution, a chiral reagent or catalyst, will promote the reaction of 
a specific enantiomer over the other due to differing reaction rates. While kinetic 
resolution is useful in synthesizing one enantiomeric product over the other, because 
reactions are performed using a racemic mixture, only half the starting material would be 





Figure 5. Theoretical kinetic resolution 
 
 
This can still be advantageous as the remaining enantioenriched starting material can 
then be used to synthesize other enantiomeric products. The use of organocatalysts for 
asymmetric synthesis is useful as they are relatively non-toxic and more environmentally 
sustainable compared to transition metal catalysts. The Petersen lab has employed the 




Figure 6. Theoretical desymmetrization cyclization of malonic esters 
 
 
As the malonic esters are symmetric at the central carbon before cyclization, 
organocatalysts, specifically chiral catalysts, induce a desymmetrization of the ester. 
This encourages enantioenrichment of the resulting lactone as the activation energy for 
a specific enantiomer would be lowered. This allows for the more favored synthesis of 





I.3 Brønsted acid catalysts 
The use of a Brønsted acid to drive the intramolecular cyclization has proved to 
be quite efficient and has the advantages of being “easy to handle and generally stable 
toward oxygen and water” while also having a relatively long shelf life.4 Some 
organocatalysts used in the Petersen lab have included p-toluenesulfonic acid, 
methylsulfonic acid, trifluoroacetic acid, and the axially chiral 3,3’-Bis(2,4,6-
triisopropylphenyl)-1,1’binaphthyl-2,2’-diylhydrogen phosphate (TRIP catalyst), as seen 




Figure 7. Brønsted acid catalysts 
 
 
The TRIP catalyst in particular has shown favorable results in the enantioselective 
desymmetrization of malonic esters to synthesize lactone derivatives. While p-
Toluenesulfonic acid, methylsulfonic acid, and trifluoroacetic acid can be used to cyclize 
the malonic esters, they produce racemates. Of the possible Brønsted acid catalysts that 
can be used to generate enantioenriched lactones, chiral phosphoric acids have shown 
the most promise for the Petersen group. As seen in Figure 8, the phosphoryl oxygens 





Figure 8. Proposed activation complex 
 
 
These hydrogen bonds serve to initiate a complex formation between the chiral Brønsted 
acid and the ester carbonyl group and the hydroxyl end group of the malonic ester. The 
electrophilic carbon atom of the ester group can then easily undergo nucleophilic attack 








The potential enantioselectivity of these Brønsted acids, particularly for 1,1’-bi-2-
naphthol (BINOL) phosphoric acids (Figure 10), is then influenced not only by the ring 




Figure 10. Structure of BINOL phosphoric Brønsted acids 
 
 
For phosphoric acid catalysts, ring systems not only “restrict the conformational flexibility 
of the chiral backbone,” but the substituents added to that ring system serve to act as 
substrate recognition site due to the dual Brønsted acid/base sites of the phosphoric 
acid and “the steric and electronic influence of the subststiuents.”17 
 
I.4 Previous Work of the Petersen Group  
As alluded to before, this research utilized the novel asymmetric synthesis 
technique developed by Dr. Jennifer Wilent of the Petersen group, who employed 
prochiral compounds, specifically malonic esters, to produce R or S lactone derivatives 
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from desymmetrization.3 The primary compounds synthesized in this work were -




Figure 11. Results from work by Dr. Wilent3 
 
 
Utilizing Dr. Wilent’s work, Dr. Amber Kelley and a PhD student Rhashanda 
Haywood sought to further examine the use of cyclic substrates in lactone synthesis 
particularly for the synthesis of coumarin derivatives. The 3,4-dihydrocoumarin 
derivatives produced from these reactions were prepared in moderate to high yields and 
the addition of a secondary alkyl group to the center of a malonic ester did not display a 
great decrease in ee with increased steric size (Figure 12). The 3,4-dihydrocoumarin 
derivatives with all carbon quaternary center were found to have not only the highest 




Figure 12. Results of Coumarin derivative synthesis 
 
 
Building from the work done by Dr. Wilent, Dr. Ghassan Qabaja was able to 
synthesize lactones from , - and , -disubstituted hydroxy esters through a kinetic 
resolution to produce enantioenriched lactone derivative diastereomers (for a select 
example see Figure 13).11 These kinetic reactions were found to favor a “dicoordination 
model” wherein the energy profiles of the most selective cyclization and its diastereomer 
were calculated and compared. The barrier heights for the most selective kinetic 
resolution were found and the more favored diastereomer was determined to have lower 




Figure 13. Results from Dr. Qabaja11 
 
 
Racemic cyclic hydroxy esters were also analyzed in this research and were found to be 
better kinetic resolution substrates and “more selective due to the conformational 
restriction that places the alcohol in closer proximity to the ester, giving a more rigid 
transition state.”11 Having a cyclic system that connected the R and R1 substituents not 
only shifted the hydroxyl terminal group closer to the ester on the ring system, but also 
inverted its position to an internal point in the compound (Figure 14), allowing for greater 




Figure 14. A sample of the results for racemic cyclic hydroxy esters11 
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While the synthesis of -lactones tends to have more prevalence than -lactones and it 
has been theorized that 5 membered ring lactones have a greater ease for cyclization 
than 6 membered ring lactones. This is likely due to the ring conformations seen in -
lactones, which typically favors the higher energy half-chair and boat conformations, 
while -lactones favor the lower energy envelope conformation.6 The focus on the 
synthesis of -lactones with multiple stereocenters, creates the opportunity to first 
generate -lactones with high diastereomeric ratios utilizing achiral Brønsted acids, and 
then single enantiomers by using chiral organocatalysts. Additionally by utilizing an 
organocatalyst, these cyclizations can be done in a milder, more stable, and more 
environmentally friendly conditions. The use of chiral Brønsted acid organocatalysts to 
cyclize symmetric diesters makes the work described in this thesis quite novel as most 
cyclizations of this nature have been done employing transition metal catalysts, like 
Platinum (Pt) or Titanium (Ti).23,24 Additionally, the work in this thesis will be novel for the 
Petersen group as the synthesis of diastereomeric lactones had not been accomplished 
utilizing diesters.   
Moreover, ROP with disubstituted -lactones has been less commonly studied, 
but the substitution to the lactone ring has been shown to “significantly affect” the 
polymerization of -lactones.16 Also based on the work done with poly(hydroxy acid)s, 
the varying properties of these different enantiomeric and diastereomeric -lactones 
could then be studied to generate novel polymers. Thus allowing for future collaborations 




DIASTEREOSELECTIVE DESYMMETRIZATIONS OF DIESTERS 
 
 
II.1 Present Work 
Building from the work published in ChemistrySelect by Dr. Kelley et al. regarding 
the synthesis of 3,4-Dihydrocoumarins18 as well as the work done by Dr. Qabaja with 
asymmetric synthesis of hydroxy esters with multiple stereocenters, this project seeks to 
show the processes developed for synthesizing -lactone diastereomers through the 




Figure 15. Retrosynthesis of diastereomers 
 
 
As alkylating agents with a second chiral center were not commercially available, they 
needed to be synthesized. A method for synthesizing a monosubstituted alkylating group 
that had a protected hydroxy group had been previously developed in the Petersen group 





Figure 16. General method for alkylating agent synthesis 
 
 
Thus starting with 2-phenyl-1,3-pronanediol, 7, and 2-methyl-1,3-propanediol, 10, these 
diols underwent monobromination by an Appel reaction. This addition of bromide 
produced compounds 8 and 11, with this new substituent acting as a more efficient 
leaving group for later substitution with any malonic ester. Next, to prevent any 
premature cyclization, the remaining unsubstituted hydroxyl group was protected with t-
butyldimethylsilylchloride (TBS-Cl) to obtain substituted (3-bromopropoxy)-tert-
butyldimethylsilanes, 9 and 12. However, the TLC visualization process was near 
impossible for purification of compounds 11 and 12, so alkylation had to be done 




Figure 17. Alkylation with secondary stereocenter 
 
 
Once these alkylating agents were created, they were added to the central carbon of a 
di-tert-butyl malonate, 1 (Figure 17). Prior work performing this alkylation had been done 
by adding the alkylating agent to the malonate 1 in a 0C ice bath with sodium hydride 
and then allowing the reaction to warm to room temperature. Initially this same 
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procedure was followed employing compound 9 as an alkylating agent that gave yields 
ranging from 4-33%, with a 33% yield occurring when the reaction was given a week to 
stir at room temperature. By modifying the reaction to warming the mixture slightly to 
room temperature after the addition of the malonate and the alkylating agent the flask 
was then heated to 70C in an oil bath. This allowed yields to almost double. As 12 does 
not have the same bulky benzene ring attached at the second carbon, the initial 
methodology for alkylation with sodium hydride in THF was performed with compound 1, 




Figure 18. Formation of the cyclization starting material 
 
 
Once this first alkylation was completed compounds 13 and 15 underwent a 
second alkylation with iodomethane to produce fully alkylated products 14 and 16. The 
tert-butyldimethylsilane protecting group was then removed with tetra-n-butylammonium 
fluoride (TBAF) to reveal the hydroxy group for compounds 2 and 17 (Figure 18). 
Compound 2 was cyclized (Figure 19) with three different achiral Brønsted acid catalysts 
(Table 1), p-Toluenesulfonic acid (p-TsA), methylsulfonic acid (MsOH), and 





Figure 19. Achiral Brønsted acid cyclization screen 
 
 
Table 1. Achiral Brønsted acid screen 
Entry Catalyst  Yield 
(%) 
dr 
1 p-TsA 70 1:4 
2 MsOH 39 3:1 
3 TFA 53 1:5 
 
 
The acid catalyst screen showed that the p-TsA had the best yields, but TFA had the 
best diastereoselectivity (entry 1 and 3, Table 1). Though the TFA did have better dr 
than the p-TsA, the p-TsA was chosen due to its structural similarity to the chiral TRIP 
catalyst. From these results, further optimization was completed by changing the 




















1 DCM r.t. 51 1:4 
2 Bromobenzene r.t. 46 1:1 
3 THF r.t. 20 N.R. 
4 Toluene r.t. 63 1:2 
6 DCE 0 N.R. N.R. 
7 DCE -78 N.R. N.R. 
8 DCE r.t. to 40 38 1:3 
9 DCE r.t. to 80 12 N.R. 
 
 
While dichloromethane (DCM, entry 1, Table 2) maintained the diastereoselectivity of p-
TsA, it did result in lower yields than dichloroethane. The other solvents also were not as 
favorable as they had both lower yields and either no reaction or lower dr (entries 2-4, 
Table 2). With DCE determined as the best solvent, the reaction temperature was 
varied, and we saw similar favorability to the original reaction conditions. Lowering 
temperature conditions (entries 6 and 7, Table 2) resulted in no reaction. In fact, the -
78C conditions caused DCE to freeze, which was later determined to be due to the 
melting point of DCE being -35C. Heating the reactions also did not improve the 
reaction as raising the temperature to 40C caused both a decrease in the dr and yield, 
while heating to 80C seemed to degrade the starting material completely (entries 8 and 
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9, Table 2). With the optimum reaction conditions for p-TsA determined, a chiral 




Figure 21. NOESY of isolated major diastereomer for cyclization of 3 with p-TsA 
 
 
Structural details for compound 3 will be further characterized by X-ray crystallography, 
but an initial hypothesis is made by Nuclear Overhauser Effect Spectroscopy (NOESY). 
This method of nuclear magnetic resonance (NMR) spectroscopy provides insight about 
the spatial interactions of the protons in a compound relative to each other. For 
compound 3 the main interaction we are interested in exploring is that of proton E on the 
secondary stereocenter and the protons on the methyl group attached to the  carbon of 
the lactone ring. As no such interaction is seen in the NOESY of the isolated major 
diastereomer (Figure 21) it can be assumed that the relative configuration of the 
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stereocenters of the -lactone would have the methyl at the  carbon located in position 
that would allow for little interaction with proton E. Thus, we predicted that the major 
diastereomer is the one shown in Figure 22A because its methyl group is in an 




Figure 22. Potential conformations of compound 3 
 
 
In an effort to produce enantioenriched diastereomers, TRIP catalyst was used to cyclize 
compound 2 (Figure 23). Initially S-TRIP was used with the optimum conditions found for 
p-TsA, but this resulted only in recovered starting material. The cyclization was 
performed twice more, by altering the TRIP catalyst as well as utilizing the reaction 
conditions similar to those for the coumarin derivatives18 (Table 3 entries 2 and 3). As 
seen for Entry 3 in Table 3, the changed from S- to R- TRIP still resulted in no reaction 
when performed with DCE as a solvent. Though the reaction with p-TsA in the 
optimization screen with bromobenzene did not have a high diastereoselectivity, there 
was a slight increase to dr when the reaction conditions were changed to those used in 
the coumarin derivative synthesis. The enantioenrichment of each diastereomer proved 
to be low to moderate with 15% ee for the major isolated diastereomer and 46% ee for 
21 
 
the minor isolated diastereomer. It can also be noted that the major and minor 




Figure 23. TRIP cyclization for compound 2 
 
 
Table 3. TRIP cyclization optimization 
Entry TRIP 
Catalyst 
Temperature Solvent Yield 
(%) 
dr eemajor eeminor 
1 S rt to 40C DCE N.R N.R N.R N.R 
2 S 100C Bromobenzene 57 2:1 15% 46% 
3 R 80C DCE N.R N.R N.R N.R 
 
 
Based on studies of reactions employing BINOL phosphoric acids, it was determined 
that there exists a correlation between the acidity of phosphoric acids and their reactivity 
provided that no catalytic inhibition takes place.20 Thus it is likely that TRIP catalyst, 
having a pKa value in the range of 12-14 compared to 8.5 value for p-TsA, was not able 
to cyclize compound 2 in the optimized reaction conditions because the acidity was not 
low enough to activate the nucleophilic attack of the hydroxyl group at temperatures at or 
below 80C. The difference in the molar equivalence of the catalyst used for cyclization 
could also factor into the difficulties in the TRIP cyclization as one equivalent of p-TsA 
was used in the optimization reactions while only 0.05-0.10 equivalents of TRIP were 
used to cyclize the product.   
22 
 
The preparation of compound 18 (Figure 23) was proposed to compare the 
diastereoselectivity of the achiral Brønsted acid catalysts. As the secondary stereocenter 
on this compound was a methyl and not a phenyl ring, it would be likely that the 
enantioselectivity of this compound would decrease as the pi stacking from the phenyl 
group that was theorized previously by the Petersen group to aid in the selectivity of the 
cyclization was no longer present.18 Unfortunately, due to issues with TLC visualization 





Figure 24. Cyclization of compound 17  
 
 
II.2 Future Work and Conclusions 
 
 While this work was able to achieve novel diastereoselectivity with Brønsted acid 
catalyzed cyclizations, further optimization and study of these results will likely need to 
be continued to promote even greater selectivity. Additionally, while the NOESY was 
able to assist in theorizing the conformation of the isolated major diastereomer of the 
cyclization with p-TsA, X-ray crystallography will be necessary to confirm the predicted 
relative stereochemistry of this diastereomer. Though it was not specified in the previous 
section the results from the reaction monitoring of Entry 2 of Table 3 indicate that longer 
reaction time might be necessary potentially leading to an increase of the dr or reaction 
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yield. This is likely as some starting material was still present when the reaction was 
stopped after a 24-hour reaction period. Additionally employing R-TRIP in conditions 
detailed in Entry 2 may reveal if the configuration of the catalyst might factor into the 
diastereo- and enantioselectivity of this cyclization. Based on the concept of 
matched/mismatched effects, it could be likely that the low diastereoselectivity seen for 
S-TRIP was due to a mismatched paring of the catalyst and the starting material and 
that utilizing R-TRIP would lead to an increase of diastereoselectivity based on a 
potentially more matched pairing where the multiple stereocenters would be situated in a 
more favorable conformation for stereocontrolled interactions.21 The main prediction 
being that the free energy differences would be greater for the matched than the 
mismatched catalyst and substrate pair.22 Next, further screening of both solvent 
systems and other BINOL phosphoric acid catalysts may provide increased selectivity as 
alterations of each reaction component may lower the activation necessary to promote 
cyclization.  Finally, expanding not only the substrate scope of the secondary alkylating 
agent but also determining a successful process for synthesizing compound 17 would 
help to validate the robustness of these novel Brønsted acid catalyzed cyclizations for 




EXPERIMENTAL PROCEDURES AND RESULTS 
 
 
III.1 General Information  
Solvents and reagents were obtained from commercial sources and did not undergo 
purification unless stated. The 1H and 13C nuclear magnetic resonance (NMR) spectra 
were conducted on the 400 and 500 MHz spectrometer at room temperature with 
chloroform-D (CDCl3) as the solvent. The NMR chemical shifts () are reported in ppm. 
Abbreviations for 1H NMR: s=singlet, d=doublet, m=multiplet, t=triplet, q=quartet. The 
reactions were monitored by TLC using silica gel (particle size: 40-63 m, 230x400 
mesh) and GC/FID analysis. Enantiomeric excess was determined by HPLC analysis. 
High Resolution Mass Spectra were acquired at UNCG Triad Mass Spectrometry 
Laboratory. 
 
III.2 Synthesis of Compound 3 








To begin N-bromosuccinimide (NBS; 5.69 g, 33.5 mmol) was added at 0 °C to a mixture 
of 7 (5.00 g, 32.9 mmol) and triphenylphosphine (PPh3; 8.59 g, 32.8 mmol) dissolved in 
dry dichloromethane (DCM; 140 mL) in a 250 mL flame dried two neck round bottom 
flask under argon. The cooling bath was removed, and the reaction allowed to warm to 
room temperature and stirred for five days. The solvent was then evaporated, and the 
product was purified by column chromatography (Silica gel, 1:5 ethyl acetate: hexane), 
to yield compound 8 as a clear yellowish liquid (4.91 g, 70% yield) which was used 
directly in the next step. 1H NMR (400 MHz, CDCl3) δ 7.40-7.25 (m, 4H), 7.23 (s, 1H), 
3.96 (d, J= 5.9 Hz, 2H), 3.81-3.68 (m, 1H), 3.64 (m, J= 10.1, 6.5 Hz, 1H), 3.20 (m, J= 6.3 
Hz, 1H) ppm 
A mixture of compound 8 (1.00 g, 18 mmol) in tetrahydrofuran (THF; 10mL) was reacted 
with imidazole (950 mg, 54 mmol) and tert-butyldimethylsilylchloride (TBS-Cl; 1.19 g, 31 
mmol) in anhydrous THF (50 mL) was stirred in a 100 mL flame dried two neck round 
bottom flask under argon at room temperature overnight. The mixture was diluted with 
water (40 mL) and extracted three times with DCM (50 mL each). The organic layers 
were combined and dried over magnesium sulfate (MgSO4), which was then filtered off. 
The mixture was then concentrated and purified by column chromatography (Silica gel, 
1:8 ethyl acetate: hexane) to obtain substituted (3-bromopropoxy)-tert-
butyldimethylsilanes, 9 as a clear liquid (1.53 g, 78% yield).  1H NMR (400 MHz, CDCl3) 
δ 7.34-7.26 (m, 2H), 7.26-7.20 (m, 3H), 3.94-3.77 (m, 3H), 3.63 (m, J= 9.9, 7.1 Hz, 1H), 
3.12 (m, J= 6.5, 4.4 Hz, 1H), 0.87 (s, 9H), -0.00 (d, J= 4.0 Hz 6H) ppm; 13C NMR (400 
MHz, CDCl3) δ 140.5, 128.5, 128.1, 127.3, 65.1, 50.2, 34.9, 25.9, 18.3, -5.4 ppm; HRMS 








Figure 26. Alkylation of compound 1 with compound 9 and iodomethane followed by deprotection 
 
 
For the first alkylation, sodium hydride (NaH; 314 mg, 7.9 mmol) in THF (80 mL) was 
cooled to 0 C in a 100 mL flame dried two neck round bottom flask under argon in an ice 
bath then the di-tert-butyl malonate 1 (1.62 mL, 7.2 mmol) was added followed by the 
alkylating agent 9 (1.18 g, 3.6 mmol) and the reaction was allowed to warm slightly to 
room temperature before placing the flask in an oil bath which was heated to ~65 C. The 
reaction was stirred overnight before being dilute with water (50 mL) and extracted 3 times 
with DCM (100 mL each). The organic layers were combined and dried over MgSO4, then 
filtered and concentrated. Compound 13 was isolated by column chromatography (Silica 
gel, 1:12.5 ethyl acetate: hexane), to yield a clear liquid (1.08 g, 65% yield). In the second 
alkylation, NaH (492 mg, 12.3 mmol) in THF (60 mL) was again cooled to 0 C in a 100 
mL flame dried two neck round bottom flask under argon in an ice bath then the substituted 
malonate 13 (2.34 g, 5.0 mmol) was added followed by iodomethane (674 L, 10.8 mmol). 
The flask was warmed to room temperature and the reaction stirred overnight, before 
being dilute with water (50 mL) and extracted with three times with DCM (100mL each). 
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The organic layers were combined and dried over MgSO4 then filtered and concentrated, 
followed by purification by column chromatography (Silica gel, 1:50 ethyl acetate: hexane) 
for a clear liquid of the fully alkylated product 14 (1.73 g, 87% yield). The tert-
butyldimethylsilane protecting group was then removed by dissolving 14 (1.32 g, 2.8 
mmol) in THF (30 mL) in a 100 mL flame dried two neck round bottom flask under argon 
in an ice bath at 0 C. Tetra-n-butylammonium fluoride (TBAF; 1.26 mL, 4.8 mmol) was 
added dropwise while stirring. The flask was stirred overnight to reach room temperature. 
The reaction was then quenched with water (30 mL) and extracted three times with DCM 
(30 mL each). The organic layers were combined and dried over MgSO4, then filtered and 
concentrated.  Compound 2 was then isolated by column chromatography (Silica gel, 
1:14.3 ethyl acetate: hexane) as a clear liquid (861 mg, 86% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.28 (d, J= 7.9 Hz, 2H), 7.21 (m, 3H), 3.69-3.57 (m, 2H), 2.80 (s, 1H), 2.32 (d, 
J= 12.8 Hz, 1H), 2.17-2.09 (m, 1H), 1.44 (s, 9H), 1.32 (s, 9H), 1.18 (s,3H) ppm; 13C NMR 
(400 MHz, CDCl3) δ 143.0, 128.8, 128.4, 127.0, 81.5, 81.4, 68.2, 54.78, 44.8, 37.0, 27.9, 
27.8, 20.5 ppm; HRMS (ESI): for C21H32O5 [M+H]+: calculated 365.2323; found 365.2314 




Figure 27. Cyclization of compound 2 
 
 
In a flame dried 50 mL round bottom flask, compound 2 (300 mg, 0.82 mmol) was 
dissolved in DCE (15 mL) before the Brønsted acid catalyst (1 equivalent, Table 1) was 
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added. The reaction was stirred overnight, before being dilute with water (15mL) and 
extracted three times with ethyl acetate (20 mL each). The organic layers were 
combined and dried over MgSO4, then filtered and concentrated. Compound 3 was then 
isolated by column chromatography (Silica gel, 1:20 to 1:6 ethyl acetate: hexane) and 
concentrated to white crystals (168 mg, 70% yield). 1H NMR (400 MHz, CDCl3) δ 7.38-
7.32 (m, 2H), 7.29 (d, J= 12.8 Hz, 3H),  4.30 (m, J= 11.1, 5.0, 1.8 Hz, 1H), 4.17 (t, J= 
11.8 Hz, 1H), 3.27 (m, J= 12.3, 10.1, 7.6, 4.9 Hz, 1H) 2.80 (m, J= 14.1, 10.1 Hz, 1H), 
2.04 (m, J= 14.2, 7.4, 1.8 Hz, 1H), 1.53 (s, 3H), 1.50 (s, 9H) ppm; 13C NMR (400 MHz, 
CDCl3) δ 171.2, 167.9, 139.0, 129.1, 127.8, 127.7, 83.0, 72.7, 50.9, 39.0, 37.6, 27.8, 
23.5 ppm; HRMS (ESI): for C17H22O4 [M+H]+: calculated 291.15; found 291.16 
 
III.3 Synthesis of Compound 17 




Figure 28. Monobromination and protection to synthesize alkylating agent 12 
  
 
NBS (6.26 g, 35.2 mmol) was added at 0 °C to a mixture of 10 (2.5 mL, 28.2 mmol) and 
PPh3 (9.23 g, 35.2 mmol) dissolved in dry DCE (200 mL) in a 250 mL flame dried two-
neck round bottom flask under argon. The cooling bath was removed, and the flask 
allowed to warm to room temperature and stirred for three days. The solvent was then 
quenched with water (100 mL) and extracted three times with DCM (75 mL each). The 
organic layers were combined and dried over MgSO4, then filtered. The product was 
then concentrated to yield compound 11 as a yellowish crystal. Due to visualization 
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issues compound 11 could not be purified by column chromatography, so it was used 
directly in the next step. Compound 11 (4.31 g, 20.0 mmol) was then placed in a 250 mL 
two-necked round bottom flask and reacted with imidazole (3.70 g, 40.1 mmol) and TBS-
Cl (5.13 g, 34.1 mmol) in anhydrous THF (50 mL) stirred at room temperature overnight. 
The mixture was diluted water (100 mL) and extracted three times with DCM (50 mL 
each). The organic layers were combined and dried with MgSO4 then filtered. The 
solvent was evaporated to obtain substituted (3-bromopropoxy)-tert-butyldimethylsilane, 
12, as a yellow liquid (2.95 g, 55% yield). Again due to visualization issues compound 12 




Figure 29. Alkylation of compound 1 with compound 12 
 
 
To a flame dried two-neck 100 mL round bottom flask, NaH (782 mg, 19.5 mmol) in THF 
(50 mL) was cooled to 0 C in an ice bath then the di-tert-butyl malonate 1 (2.99 mL, 
13.2 mmol) was added followed by the alkylating agent 12 (2.95 g, 11.0 mmol) and the 
reaction was allowed to warm slightly to room temperature. The reaction was stirred for 
three days before being dilute with water (50 mL) and extracted three times with DCM 
(25 mL each). The organic layers were combined and dried over MgSO4, then filtered. 
The solvent was evaporated and compound 15 was isolated by column chromatography 
(Silica gel, 15% ethyl acetate: hexane) and concentrated to a yellow liquid (2.17 g, 49% 
yield). 1H NMR (400 MHz, CDCl3) δ 4.08 (t, J= 6.7 Hz ,3H), 3.56-3.49 (m, 1H), 3.48-3.35 
(m, 2H), 1.45 (s, 9H), 1.43 (s, 9H), 0.87 (s, 9H), 0.01 (s, 6H) ppm; 13C NMR (400 MHz, 
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CDCl3) δ 167.2, 82.1, 67.0, 44.5, 28.3, 26.0, 22.0, 10.4, -5.3 ppm; HRMS (ESI): for 
C21H42O5Si [M+H]+: calculated 403.2874; found 403.2868  




Figure 30. Alkylation of Compound 15 with iodomethane followed by deprotection 
 
 
In the second alkylation, NaH (406 mg, 10.2 mmol) in THF (50 mL) was cooled to 0 C in 
a 100 mL flame dried two neck round bottom flask under argon in an ice bath then the 
substituted malonate 15 (1.95 g, 5.0 mmol) was added followed by iodomethane (674 L, 
10.8 mmol). The flask was warmed to room temperature and stirred overnight, before 
being dilute with water (50 mL) and extracted three times with DCM (20 mL each). The 
organic layers were combined and dried over MgSO4, then filtered. The solvent was 
evaporated and purified by column chromatography (Silica gel, 5% ethyl acetate in 
hexane) for a fully alkylated product 16. The product was concentrated to a light orange 
colored liquid (908 mg, 45%yield). The tert-butyldimethylsilane protecting group was then 
removed by dissolving 16 (908 mg, 2.2 mmol) in THF (20 mL) in a 100 mL flame dried two 
neck round bottom flask under argon, then cooling it to 0 C in an ice bath. TBAF (3.27 
mL, 3.27 mmol) was added dropwise while stirring. The reaction was stirred overnight to 
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reach room temperature. The reaction was then quenched with water (20 mL) and 
extracted three times with DCM (15 mL each). The organic layers were combined and 
dried over MgSO4, then filtered Compound 17 was then isolated by column 
chromatography (Silica gel, 7% ethyl acetate in hexane). The product was concentrated 
to a light-yellow liquid (40 mg, 6%yield). Peaks from spectra do not correlate with what 
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The 1H and 13C nuclear magnetic resonance (NMR) spectra were plotted on 400 
MHz spectrometer using CDCl3 as a solvent at room temperature. The NMR chemical 
shifts (δ) are reported in ppm. Abbreviations for 1H NMR: s = singlet, d = doublet, m = 

















































HPLC chromatograms were obtained using an Agilent 1260 Infinity with diode array 
detector (DAD) and a CHRIALCEL AD-H (4.6 mm x 250 mm x 5 m) chiral column. 
Analysis details can be found with the chromatogram. High Resolution Mass Spectra 
were acquired at UNCG Triad Mass Spectrometry Laboratory. 
 






HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 




























Bromobenzene (Minor Product) 
 
 
Bromobenzene (Major Product) 
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